Connect with us

Press Release

CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

Published

2 months ago

on

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the “Agreement”) with Pharmacosmos A/S for Iron Isomaltoside Injection (“Monofer®”) and Iron Dextran Injection (“Cosmofer®”) recently. In accordance with the Agreement, the Group has obtained an exclusive right to commercialize the products in the People’s Republic of China (for the purpose of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan region). Pharmacosmos A/S will continue to manufacture and supply the products. The cooperation term shall be fifteen years from the effective date stipulated in the Agreement, which may be extended upon mutual agreement between the parties prior to expiry.

 

The two intravenous iron therapies under this cooperation are both originator products that have been approved for marketing in China and included in the China’s National Reimbursement Drug List (NRDL). Among them, Monofer® is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China. It features an innovative and more stable matrix-like nanostructure and provides a superior safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Another product, Cosmofer®, is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the National Essential Medicines List (NEML). With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data.

 

The above two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, which can support meeting the clinical needs of different levels of healthcare institutions and different types of iron deficiency anemia (IDA) patients, providing more diversified, safe and effective treatment options for patients. Patients with iron deficiency (ID) and IDA are widely distributed across multiple clinical departments, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics, which are all key specialty areas of the Group. The addition of the two products will generate efficient synergies with the Group’s existing marketed products in expert resources and academic promotion network, further strengthening the Group’s overall competitiveness in the field of anemia treatment, and is expected to have a positive impact on the Group’s performance.

 

More information about Monofer®

Monofer® was approved on 30 January 2021 for the treatment of iron deficiency in patients where oral iron preparations are ineffective, cannot be used, or where there is a clinical need for rapid iron supplementation. In 2023, Monofer® was included in the NRDL as a Category B reimbursable drug. Monofer® consists of nanoparticles with a stable, matrix-like structure composed of interchanging layers of iron atoms and short, linear isomaltose carbohydrates. This structure enables controlled iron release with low levels of labile iron, contributing to a favourable safety profile, including a low risk of hypersensitivity reactions and hypophosphatemia. Monofer® can be administered as a high-dose infusion of 1,000 mg or more in a single visit, whereas older therapies such as iron sucrose typically require repeated administrations of 100 to 200 mg. This enables full iron repletion in one treatment, reducing the need for multiple infusions, lowering the burden on patients and healthcare systems, and increasing infusion capacity. At the same time, the low risk of hypophosphatemia helps avoid complications such as fractures and supports recovery from fatigue, a key symptom of iron deficiency anaemia.

 

More information about Cosmofer®

Cosmofer® is a second-generation low-molecular-weight iron dextran injection. It was approved for marketing in Mainland China in 2003 and is indicated for patients with iron deficiency who cannot take oral iron preparations (such as those who are intolerant to oral iron or have unsatisfactory therapeutic outcomes). Cosmofer® also allows single-dose high-dose iron repletion. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Its dual status as a Category A NRDL-listed product and NEML supports its core role in iron supplementation in primary healthcare settings.

 

About Iron Deficiency and Iron Deficiency Anemia

ID and IDA are global health issues that commonly affect children, premenopausal women (particularly pregnant women) and the elderly. These conditions may impair the function of multiple organ systems, leading to a series of health problems such as growth retardation, behavioral disorders, cognitive impairment, reduced physical capacity, and peri-natal and peri-operative complications. They also significantly affect the prognosis of chronic diseases such as gastrointestinal diseases, chronic kidney disease, heart failure and tumors[2]. More than 1 billion people live with iron deficiency anaemia[3], making it one of the leading contributors to the global burden of disease[4]. Data from the Fourth National Nutrition Survey in China indicate that the prevalence of IDA among Chinese residents is 20.1%[5]. However, both patients and healthcare professionals have insufficient awareness of the disease. Less than 20% of patients with mild anemia receive diagnosis and treatment, while only about 50% of patients with severe anemia receive appropriate diagnosis and treatment[2]. This indicates significant underdiagnosis and undertreatment of ID/IDA. Iron supplementation is the standard treatment for ID/IDA and includes oral iron therapy and intravenous iron therapy. Intravenous iron therapy is an important option for patients who cannot tolerate oral iron, have inadequate response to oral therapy, require rapid iron repletion, or prefer full iron supplementation within one to two administrations[1,2,6]. However, due to insufficient awareness of IDA, patient adherence issues, hospitalization constraints, infusion convenience, and safety concerns regarding intravenous iron therapies, the clinical use of intravenous iron in China remains relatively conservative. A Chinese real-world study shows that the average total dose of iron sucrose used in IDA patients was approximately 511 mg, which was significantly lower than the target dose of 1,000 mg[2]. There is therefore a significant clinical need for intravenous iron therapies that offer high safety, strong demonstrated efficacy and single-dose full iron repletion. Monofer® and Cosmofer® together establish a comprehensive intravenous iron product portfolio covering multiple treatment scenarios, providing tiered treatment options for patients with iron deficiency anemia.

 

About Pharmacosmos A/S

Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anemia. Leveraging its deep expertise in carbohydrate chemistry and cell cycle biology, the company is committed to developing innovative therapies to address unmet patient needs, with a particular focus on iron metabolism and hematology-related diseases. Pharmacosmos A/S was founded in 1965 and is headquartered in Denmark, and employs more than 700 specialists from the United Kingdom, Ireland, the Nordic countries, Germany, the United States, Canada and China. With excellent product quality and strong clinical value, its core iron therapy products have been approved and widely used in multiple countries and regions worldwide, establishing strong technological capabilities and a solid market reputation.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

 

Reference:

  1. Chinese Pharmacological Society Professional Committee of Drug‑induced Diseases, Guangdong Pharmaceutical Association. Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024) [J]. Adverse Drug Reactions Journal, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃00070
  2. Liao Minjing, Zhang Liansheng. Standardized diagnosis and treatment of iron deficiency and iron‑deficiency anemia [J]. Chinese Journal of Internal Medicine, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.
  3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.
  4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.
  5. Li Lijuan, Zhang Liansheng. Considerations on the standardized diagnosis and treatment of iron‑deficiency anemia [J]. National Medical Journal of China, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.
  6. Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition) [J]. National Medical Journal of China, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Umamusume Pretty Derby 7th EVENT WORLD TOUR THE STAGE in TOKYO broadcast ABEMA Live in 20 countries

Published

10 minutes ago

on

June 22, 2026

By

Over 40 Umamusume cast members will take the stage across the two-day event!Umamusume’s First-Ever World Tour Debuts in Tokyo!

Tokyo, Japan, 22nd Jun 2026 – Japan’s video streaming service ABEMA has announced that it has broadcast rights for the concert event Umamusume: Pretty Derby – 7th EVENT WORLD TOUR: THE STAGE in TOKYO, taking place on Saturday, June 20 and Sunday, June 21, 2026, via its global online live platform ABEMA Live. The live broadcast will be available worldwide in 20 countries and regions, including the United States, South Korea, and Thailand.

Umamusume Pretty Derby – 7th EVENT WORLD TOUR: THE STAGE is the first-ever world tour in the concert history of the highly popular cross-media franchise Umamusume Pretty Derby (hereafter “Umamusume”). A star-studded cast will come together to deliver a thrilling concert experience that takes fans into the world of Umamusume, making this a must-see event. For the Tokyo performance, over 40 cast members will gather across the two-day concert, including Machico (Tokai Teio), Tomoyo Takayanagi (Oguri Cap), and Hitomi Ueda (Gold Ship). Fan excitement for the performance continues to rise as the day approaches.

This concert will be broadcast in 20 countries and regions worldwide—including the United States, South Korea, Thailand, and the Philippines—via the global online live platform ABEMA Live, which allows users outside Japan to purchase (*1) and watch (*2) a variety of pay-per-view content such as artist concerts, events, and sports broadcasts distributed on ABEMA.

Tickets for ABEMA Live are currently on sale via each country’s purchase page. For more details about ABEMA Live, please check the page below.
ABEMA Live page: https://www.abema-global.com

The Umamusume concerts always generate a huge buzz. What kind of performance will unfold on the first-ever world tour? Be sure to catch the moment a new landscape opens up for yourself on ABEMA.

*1 Payment methods available are credit card and PayPal.
*2 Viewing tickets cannot be purchased in supported regions, including Japan.

Broadcast date and time
Day 1: Saturday, June 20, 2026, show starts at 17:00 (streaming begins at 16:00) JST
Day 2: Sunday, June 21, 2026, show starts at 17:00 (streaming begins at 16:00) JST

On-demand viewing period
Day 1: Until 23:59 on Saturday, July 4, 2026 (JST)
Day 2: Until 23:59 on Sunday, July 5, 2026 (JST)

Sales period
2-Day Ticket: May 27, 2026 (Wednesday) 22:00 to July 4, 2026 (Saturday) 20:00 JST
Day 1 Ticket: May 27, 2026 (Wednesday) 22:00 to July 4, 2026 (Saturday) 20:00 JST
Day 2 Ticket: May 27, 2026 (Wednesday) 22:00 to July 5, 2026 (Sunday) 20:00 JST

ABEMA Live: Purchase Page for Available Countries
Day 1： https://www.abema-global.com/lives/3kjxdnsYCzsum7apnkqfRu
Day 2： https://www.abema-global.com/lives/gecvHpMAMBAZWBtKCXpeSr

Media Contact

Organization: CyberAgent, Inc.

Contact Person: CyberAgent, Inc. Press Contact

Website: https://caanime.cyberagent.co.jp/en/

Email: Send Email

Address:40-1 Udagawacho, Abema Towers, Shibuya City, Tokyo

City: Tokyo

Country:Japan

Release id:46335

The post Umamusume Pretty Derby 7th EVENT WORLD TOUR THE STAGE in TOKYO broadcast ABEMA Live in 20 countries appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Isilumko Activate Outlines Q2 Activation Priorities for Brand Growth

Published

53 minutes ago

on

June 22, 2026

By

Isilumko Activate has outlined a Q2 activation framework for brands seeking to convert early-year planning into measurable market activity.

Sandton, Gauteng, South Africa, 22nd Jun 2026 — Isilumko Activate has outlined a Q2 activation framework for brands seeking to convert early-year planning into measurable market activity. The company said the second quarter is often the point at which commercial expectations become more immediate, requiring brands to move from budget alignment and campaign planning into disciplined execution. In response, the agency is encouraging marketers to treat Q2 as a critical period for visibility, retail presence and campaign momentum.

According to Isilumko Activate, Q2 is where activation strategy becomes operational. The first quarter often centers on forecasting, planning cycles and internal alignment, while the next phase demands consistent delivery in market. If brands delay activation activity for too long, the awareness created by earlier campaigns can begin to weaken and competitive space can narrow. The agency said the objective in Q2 is not simply to remain active, but to build continuity between strategy, field execution and business goals.

A central part of that approach is sustained visibility. Brand presence is not usually built through a single event or isolated campaign burst. It is reinforced over time through repeated, relevant exposure across the right environments. Isilumko Activate said activation planning in Q2 should therefore be tied to a broader visibility strategy that supports recall, product understanding and the consistency of brand presentation across touchpoints.

The agency also said activations should be linked directly to specific commercial priorities. In practice, that may include supporting mid-year sales targets, driving awareness for a new or existing product, improving retail presence, encouraging product trial or re-engaging audiences after first-quarter activity. When those objectives are defined clearly at the outset, activation becomes easier to plan, easier to evaluate and more useful to the wider business.

Execution quality is another major focus in the company’s Q2 guidance. A strong strategy can lose value quickly if field delivery is inconsistent. Isilumko Activate said campaign performance is shaped not only by the idea behind the activation, but by the quality of promoter engagement, the clarity of product communication, the professionalism of the physical setup and the consistency of standards across locations. For brands running activity nationally or across multiple outlets, those details can strongly influence campaign outcomes.

The company recommends a structured Q2 operating model that combines upfront planning with practical performance management. That includes campaign timelines aligned to business calendars, staffing models built for the scale of the rollout, supervision processes that protect delivery quality and reporting systems that allow adjustments during the campaign rather than only after it ends. In this model, execution is treated as an ongoing management discipline rather than a final implementation step.

Isilumko Activate added that Q2 should be viewed as a momentum-building period, not just a maintenance window. Activity during the middle of the year can help brands strengthen their presence before larger trading periods, refine messaging before later campaign pushes and create a steadier rhythm of engagement in the market. For brands that want stronger second-half performance, Q2 can provide the operational foundation needed to carry momentum forward.

Founded in 1995, Isilumko Activate supports clients with brand activations, experiential marketing and field-based campaign execution across South Africa. The company operates in Johannesburg, Pretoria, Durban, Cape Town and Gqeberha and works with businesses seeking practical, market-facing activation programs aligned to commercial outcomes. Through its Q2 perspective, the agency said it aims to help marketers make more deliberate decisions about timing, execution and brand visibility during a key point in the annual planning cycle.

For more information, visit https://isilumkoactivate.co.za/ or contact Gregory Martin at gregory.martin@isilumko.co.za.

About Isilumko Activate
Isilumko Activate is a South African brand activation and experiential marketing agency founded in 1995. The company operates in Johannesburg, Pretoria, Durban, Cape Town and Gqeberha, supporting clients with planning, staffing and execution for activation-led campaigns across multiple market environments

Media Contact

Organization: Isilumko Activate

Contact Person: Cheris Smal

Website: https://isilumko.co.za/

Email: Send Email

Contact Number: +27662386186

Address:Unit G, La Rocca Office Park

Address 2: 321 Main Rd, Bryanston

City: Sandton

State: Gauteng

Country:South Africa

Release id:46337

The post Isilumko Activate Outlines Q2 Activation Priorities for Brand Growth appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Isilumko Activate Shares Winter Activation Insight for South African Brands

Published

53 minutes ago

on

June 22, 2026

By

Isilumko Activate has released a winter activation perspective for brands planning campaigns across South Africa.

Sandton, Gauteng, South Africa, 22nd Jun 2026 — Isilumko Activate has released a winter activation perspective for brands planning campaigns across South Africa, highlighting the value of maintaining a physical market presence during quieter seasonal periods. The company said winter often changes how consumers move through retail environments, but it does not remove the need for visibility, recall and meaningful engagement. As a result, the agency is encouraging marketers to adapt their activation formats rather than reduce activity altogether.

According to Isilumko Activate, winter planning should focus less on volume and more on relevance, timing and execution quality. In many categories, the challenge is not simply reaching consumers, but doing so in a way that fits the pace and conditions of the season. That means selecting the right environment, refining the message, and making each consumer interaction more intentional.

The agency’s winter guidance emphasizes a practical operating model for on-the-ground activity. Indoor and high-dwell environments can become more important during colder periods, while shorter but sharper engagements may deliver better results than formats designed for warmer, longer-stay conditions. Clear product communication, well-briefed teams and a professionally executed setup remain central to campaign performance, particularly when every consumer interaction must work harder.

Isilumko Activate said brands should also consider how winter affects different trade environments across the country. Retail behavior is not identical from region to region, and campaign planning should reflect local context, shopper movement and venue realities. For that reason, the agency recommends activation planning that combines national consistency with regional flexibility, especially for brands running campaigns across multiple provinces and channels.

Another priority is alignment between activation activity and business objectives. Winter campaigns are most effective when they are built around a specific commercial outcome, such as maintaining visibility, supporting product awareness, encouraging trial, strengthening retail presence or reinforcing the momentum of earlier campaigns. When activations are treated as part of the broader growth plan rather than as isolated events, the role of the channel becomes easier to measure and easier to scale.

Execution remains a defining factor. Even a strong creative concept can underperform if operational standards are inconsistent from one location to the next. Isilumko Activate said winter activations should be supported by clear staffing plans, tight briefing processes, dependable supervision and performance reporting that gives clients a usable view of what is happening in the field. In seasonal periods where attention can be harder to win, professional delivery becomes even more important.

The company added that winter is also a useful time for brands to strengthen discipline before larger seasonal trading windows later in the year. Campaigns run during quieter periods can help teams refine messaging, test operational models, improve field reporting and build a steadier market presence ahead of peak activity. In that sense, winter can function as both a performance period and a preparation period.

Isilumko Activate provides brand activation, experiential marketing and in-store campaign support for businesses across South Africa. Founded in 1995, the company operates in Johannesburg, Pretoria, Durban, Cape Town and Gqeberha, supporting clients with activation planning, field execution and market-facing engagement programs. The agency said its winter perspective is intended to help marketers make more disciplined decisions about presence, execution and return on activity during the colder months.

For more information, visit https://isilumkoactivate.co.za/ or contact Gregory Martin at gregory.martin@isilumko.co.za.

About Isilumko Activate
Isilumko Activate is a South African brand activation and experiential marketing agency founded in 1995. The company works with clients across multiple sectors and operates in Johannesburg, Pretoria, Durban, Cape Town and Gqeberha, with a focus on planning and executing market-facing campaigns that connect brands with consumers in real-world environments.

Media Contact

Organization: Isilumko Activate

Contact Person: Cheris Smal

Website: https://isilumko.co.za/

Email: Send Email

Contact Number: +27662386186

Address:Unit G, La Rocca Office Park

Address 2: 321 Main Rd, Bryanston

City: Sandton

State: Gauteng

Country:South Africa

Release id:46336

The post Isilumko Activate Shares Winter Activation Insight for South African Brands appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us